Clinical Study
Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Table 2
Baseline characteristics: randomized and expose patients.
| | Placebo () | Rimonabant 20 mg () | Overall |
| | Weight (kg) | | | | | Mean (SD) | 82.00 (16.40) | 80.95 (14.90) | 81.48 (15.67) | | Waist (cm) | | | | | Male, (%) | | | | | >90 cm | 97 (94.2%) | 92 (92.9%) | 189 (93.6%) | | Female, (%) | | | | | >80 cm | 209 (94.6%) | 211 (96.3%) | 420 (95.5%) | | BMI (kg/m2) | | | | | Mean (SD) | 30.45 (4.41) | 30.07 (4.04) | 30.26 (4.23) | | BMI group, (%) | | | | | <25 | 1 (0.3%) | 1 (0.3%) | 2 (0.3%) | | 69 (21.3%) | 70 (22.0%) | 139 (21.7%) | | >27 | 254 (78.4%) | 247 (77.7%) | 501 (78.0%) | | HDL-cholesterol (mmol/L) | | | | | Mean (SD) | 1.35 (0.29) | 1.35 (0.29) | 1.35 (0.29) | | HDL-cholesterol group, n (%) | | | | | M: <1.036, F: <1.295 | 100 (30.9%) | 119 (37.4%) | 219 (34.1%) | | Triglycerides (mmol/L) | | | | | Mean (SD) | 1.57 (1.01) | 1.59 (0.98) | 1.58 (0.99) | | Triglycerides group, (%) | | | | | ≥1.69 | 99 (30.7%) | 101 (31.9%) | 200 (31.3%) | | LDL-cholesterol (mmol/L) | | | | | Mean (SD) | 3.08 (0.72) | 3.01 (0.72) | 3.04 (0.72) | | LDL-cholesterol group, (%) | | | | | ≥3.36 | 113 (34.9%) | 97 (30.5%) | 210 (32.7%) | | Total/HDL-cholesterol | | | | | Mean (SD) | 3.70 (0.96) | 3.65 (0.97) | 3.67 (0.97) | | Fasting glucose (mmol/L) | | | | | Mean (SD) | 5.07 (0.48) | 5.17 (0.56) | 5.12 (0.52) | | Fasting glucose group, (%) | | | | | IFG: ≥5.55 and <6.99 | 43 (13.4%) | 68 (21.5%) | 111 (17.4%) | | Fasting insulin (pmol/L) | 92.04 (57.41) | 98.30 (158.08) | 95.17 (118.8) | | Mean (SD) | | | | | HbA1c (%) | | | | | Mean (SD) | 5.56 (0.39) | 5.61 (0.41) | 5.59 (0.40) |
|
|
BMI: body mass index. HDL: high-density lipoprotein. IFG: impaired fasting glucose. LDL: low-density lipoprotein. HbA1c: glycosylated hemoglobin.
|
